Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells

  • Putri, Herwandhani (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Jenie, Riris Istighfari (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Handayani, Sri (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Kastian, Ria Fajarwati (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada) ;
  • Meiyanto, Edy (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada)
  • Published : 2016.05.01


A salt compound of a curcumin analogue, potassium pentagamavunon-0 (K PGV-0) has been synthesized to improve solubility of pentagamavunon-0 which has been proven to have anti-proliferative effects on several cancer cells. The purpose of this study was to investigate cytotoxic activity and metastasis inhibition by K PGV-0 alone and in combination with achemotherapeutic agent, doxorubicin (dox), in breast cancer cells. Based on MTT assay analysis, K PGV-0 showed cytotoxic activity in T47D and 4T1 cell lines with $IC_{50}$ values of $94.9{\mu}M$ and $49.0{\pm}0.2{\mu}M$, respectively. In general, K PGV-0+dox demonstrated synergistic effects and decreased cell viability up to 84.7% in T47D cells and 62.6% in 4T1 cells. Cell cycle modulation and apoptosis induction were examined by flow cytometry. K PGV-0 and K PGV-0+dox caused cell accumulation in G2/M phase and apoptosis induction. Regarding cancer metastasis, while K PGV-0 alone did not show any inhibition of 4T1 cell migration, K PGV-0+dox exerted inhibition. K PGV-0 and its combination with dox inhibited the activity of MMP-9 which has a pivotal role in extracellular matrix degradation. These results show that a combination of K PGV-0 and doxorubicin inhibits cancer cell growth through cell cycling, apoptosis induction, and inhibition of cell migration and MMP-9 activity. Therefore, K PGV-0 may have potential for development as a co-chemotherapeutic agent.


K PGV-0;doxorubicin;breast cancer;cell lines;apoptosis;cell cycling;metastasis


  1. Da'i M (2008). Mekanisme molekuler aktivitas analog kurkumin pentagamavunon terhadap sel kanker payudara (T74D). dissertation.
  2. Ghatak N, Basu N (1972). Sodium curcuminate as an effective anti-inflammatory agent. Indian J Experimental Biol, 10, 235-6.
  3. Lin SS, Lai KC, Hsu SC, et al (2009). Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and-9 and Vascular Endothelial Growth Factor (VEGF). Cancer Letters, 285, 127-33.
  4. Margono SA, Verawati EY (2005). Sintesis kalium pentagamavunonat-0 meng-gunakan kalium hidroksida dengan pelarut tetrahidrofuran-etanol. Majalah Farmasi Indonesia, 16, 239-45.
  5. Meiyanto E, Putri D, Susidarti RA, et al (2014). Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev, 15, 179-84.
  6. Moreira AC, Branco AF, Sampaio SF, et al (2014). Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1842, 2468-78.
  7. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunological Methods, 65, 55-63.
  8. Mukhopadhyay A, Basu N, Ghatak N, et al (1982). Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents and actions, 12, 508-15.
  9. Parhi P, Mohanty C, Sahoo SK (2012). Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discovery Today, 17, 1044-52.
  10. Park C, Kim GY, Kim GD, et al (2006). Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncology Reports, 15, 1225-31.
  11. Prasad CP, Rath G, Mathur S, et al (2009). Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/${\beta}$-catenin signaling. Chemico-Biological Interactions, 181, 263-71.
  12. Sandur SK, Ichikawa H, Pandey MK, et al (2007). Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radical Biol Med, 43, 568-80.
  13. Sugiyama T, Sadzuka Y (1999). Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Clinical Cancer Res, 5, 413-6.
  14. Tacar O, Sriamornsak P, Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharmacy Pharmacol, 65, 157-70.
  15. Tonnesen HH, Masson M, Loftsson T (2002). Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharmaceutics, 244, 127-35.
  16. Yang K, Ma L, Cheng X, et al (2014). Effect of low-molecular-weight heparin combined with doxorubicin on hepatocellular cancer cell migration in vitro. J Southern Medical University, 34, 1048-52.
  17. Yoysungnoen P, Wirachwong P, Bhattarakosol P, et al (2005). Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clinical Hemorheol Microcirculat, 34, 109-15.